Jun 09, 2020
The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study
Jan 06, 2020
Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
Dec 23, 2019
Kadimastem Announces the Completion of Treatment for Cohort B of Its Phase 1/2a Clinical Trial in ALS Patients
Dec 09, 2019
Muscular Dystrophy Association Names Sharon Hesterlee, Ph.D., Executive Vice President, Chief Research Officer
Dec 04, 2019
New ALS Association Partnership with ALS Investment Fund Targets $100 Million in New Funding for ALS Therapeutic Development
Nov 18, 2019
Kadimastem Intends to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol Following Recent Positive Interim Results
Nov 11, 2019
Kadimastem to Present Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv, Israel
Jul 17, 2019
Larry Green to Receive 2019 Augie's Quest Founder's Award
Jun 04, 2019
Ice Bucket Challenge dramatically accelerated the fight against ALS
Nov 28, 2018
ALS Organizations Collaborate to Advance New Therapeutic into Trials
May 04, 2018
MDA And ALS ONE Form New Partnership To Accelerate ALS Biomarker Research
Mar 26, 2018
Orangetheory Fitness Raises More Than $4 Million to Find a Cure for ALS
Dec 05, 2017
Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (Edaravone) At 28th International Symposium on ALS/MND in Boston
Nov 22, 2017
ALS Canada awards $3 million for 12 new research projects to help make amyotrophic lateral sclerosis (ALS) a treatable, not terminal disease
Aug 08, 2017
First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S.